Age-related macular degeneration treatment
US10000753B2 · kind B2 · utility
1Cited by
3References
23Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 8, 2014 |
| Grant date | Jun 19, 2018 |
| Priority date | — |
| Expiry date | Jan 8, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2330/51
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
This invention is directed to an RNA interference (RNAi) agent and the use of that RNAi agent to treat Age-related Macular Degeneration, as well as pharmaceutical compositions containing the RNAi agents of the invention. The RNAi agent is a DNA-directed RNA interference (ddRNAi) agent (being an RNA molecule), together with an expression cassette or construct to express that agent in a cell (including in vivo), for inhibiting, preventing or reducing expression of an AMD associated gene. Preferably that AMD associated gene is one that is associated with wet AMD.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.